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Background: Myotonic dystrophy type 1 (DM1) is associated with increased cardiac morbidity and mortality.
Therefore, assessment of cardiac involvement and risk stratification for sudden cardiac death is crucial. Nevertheless,
optimal screening-procedures are not clearly defined. ECG, echocardiography and Holter-monitoring are useful but
insufficient. Cardiovascular magnetic resonance (CMR) can provide additional information of which myocardial
fibrosis may be relevant.
The purpose of this study was to describe the prevalence of myocardial fibrosis in patients with DM1 assessed by
CMR, and the association between myocardial fibrosis and abnormal findings on ECG, Holter-monitoring and
echocardiography.
Methods: We selected 30 unrelated patients with DM1: 18 patients (10 men, mean age 51 years) with, and 12
patients (7 men, mean age 41 years) without abnormal findings on ECG and Holter-monitoring.
Patients were evaluated with medical history, physical examination, ECG, Holter-monitoring, echocardiography and
CMR.
Results: Myocardial fibrosis was found in 12/30 (40%, 9 men). The presence of myocardial fibrosis was associated
with the following CMR-parameters: increased left ventricular mass (median (range) 55 g/m2 (43–83) vs. 46 g/m2
(36–64), p = 0.02), increased left atrial volume (median (range) 52 ml/m2 (36–87) vs. 46 ml/m2 (35–69), p = 0.04) and
a trend toward lower LVEF (median (range) 63% (38–71) vs. 66% (60–80), p = 0.06). Overall, we found no association
between the presence of myocardial fibrosis and abnormal findings on: ECG (p = 0.71), Holter-monitoring (p = 0.27)
or echocardiographic measurements of left ventricular volumes, ejection fraction or global longitudinal strain
(p = 0.18).
Conclusion: Patients with DM1 had a high prevalence of myocardial fibrosis which was not predicted by ECG,
Holter-monitoring or echocardiography. CMR add additional information to current standard cardiac assessment
and may prove to be a clinically valuable tool for risk stratification in DM1.
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Figure 1 CMR standard views. CMR images with normal chamber
dimensions (four-chamber view on the left and short-axis view on
the right).
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Myotonic dystrophy type 1 (DM1) is an autosomal dom-
inantly inherited neuromuscular disorder caused by an
unstable expansion of a tri-nucleotide (CTG) repeat on
chromosome 19 in the 3’ untranslated region of the
myotonic dystrophy protein kinase gene [1].
The cardiac phenotype of DM1 is complex and includes
an increased risk of conduction disturbances, arrhythmias,
compromised systolic and diastolic function and an ap-
proximately three-fold higher risk of sudden cardiac death
(SCD) compared to age-matched healthy controls [2-4].
Additionally, disease progression is unpredictable, ne-
cessitating regular and repeated cardiac assessment and
risk stratification for SCD [3,4]. According to Groh and
co-authors, the presence of conduction disturbances,
such as atrioventricular block (AVB) grade I and a clin-
ical diagnosis of atrial tachyarrhythmia, are independent
predictors of SCD [2]. Nevertheless, ECG, Holter and
echocardiographic parameters are not sufficient for pre-
diction of SCD.
Myocardial fibrosis has been identified in myocardial
autopsies from patients with DM1 together with fat in-
filtration and myocyte hypertrophy and degeneration
[5-7]. These findings are similar to observations in myo-
cardial autopsies from other non-ischemic cardiomyop-
athies [5-8]. Myocardial fibrosis may not only explain
the abnormalities in the cardiac conduction system but
also work as a substrate for supraventricular and ven-
tricular arrhythmias. Additionally, it may have a central
role in the development of the systolic dysfunction
observed in patients with DM1 [2,7,9,10].
Cardiovascular magnetic resonance (CMR) is a well-
established, non-invasive method to quantify heteroge-
neous myocardial fibrosis and assess left ventricular
function and mass [11]. Screening procedures are needed
for early detection of subclinical cardiac involvement in
patients with DM1 and to identify those at high risk of
SCD. CMR might become an essential screening-tool for
identification of high-risk patients.
We investigated 30 unrelated and genetically verified
DM1 patients with CMR and routine clinical screening
to evaluate whether CMR add additional information
about subclinical myocardial changes. In addition, our
aim was to describe the prevalence and localization of
myocardial fibrosis on CMR and to assess whether myo-
cardial fibrosis was associated with abnormal findings on
ECG, Holter-monitoring and echocardiography.
Methods
Study design
The study was conducted at the Departments of Cardi-
ology and Neurology, Rigshospitalet, Copenhagen Uni-
versity Hospital, Rigshospitalet, Copenhagen, Denmark.
We included a subgroup of patients (n = 30) from ourcross-sectional study consisting of 129 genetically veri-
fied DM1 patients [4]. Except for CMR, methodology
has previously been described in detail [4].
In brief, patients were evaluated with medical history,
physical examination, 12-lead electrocardiogram (ECG),
trans-thoracic echocardiography (including global longi-
tudinal strain (GLS), 48-hour ECG-monitoring (Holter-
monitoring) and CMR with late gadolinium enhancement
(LGE). Blood samples were analyzed for plasma levels of
NT-proBNP, myoglobin and creatine kinase (CK).
The study was approved by the regional scientific ethics
committee (reference number H-d-2008-077) and all par-
ticipating patients provided written informed consent.
Study population
A total of 30 patients were included for CMR; 18 patients
(10 men, mean age 51 years) with, and 12 patients (7 men,
mean age 41 years) without abnormal findings on ECG
and Holter-monitoring. Patients matched the main cohort
in regard to age, gender and cardiac involvement and none
of the patients were related. Patients with contraindica-
tions for CMR e.g. respiratory assist devices and claus-
trophobia were excluded, and few patients declined
participation due to severe muscular impairment.
The diagnosis of DM1 (based on CTG-repeat length)
was confirmed either by Southern blot analysis and/or
by TP-PCR [1,12].
Cardiovascular magnetic resonance
CMR was performed using a 1.5 Tesla magnetic reson-
ance scanner using a 6-channel body array coil (Avanto,
Siemens, Erlangen, Germany). Balanced steady-state free
precession end-tidal breath hold cine images were acquired
in the two-, three-, and four-chamber views followed
by contiguous short-axis plane slices covering the entire
left ventricle (LV) (echo time 1.5 ms, resolution matrix
192×192, field of view 300–360 mm, phases 25, slice thick-
ness 8 mm without interpolated gap) (Figure 1). LV volume
measurements were performed by tracing endocardial
borders in the short-axis stack images. Correct time
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end-systolic volume (LVESV) were automatically de-
fined according to the size of the blood pool area, and
LV ejection fraction (LVEF) was calculated accordingly.
Papillary muscles were considered as part of the LV
lumen. LV mass was measured at end-diastole by manu-
ally tracing the epicardial borders. To assess myocardial
late gadolinium enhancement (LGE), we used T1-weightet
inversion recovery gradient echo sequence (echo time
1.4 ms, resolution matrix 192×192 and field of view,
300–360 mm). Images were obtained 10 minutes after
intravenous bolus injection of 0.1 mmol/kg body weight
gadolinium-diethylenetriamine pentaacetic acid (Gadovist,
Bayer Schering, Berlin, Germany). The inversion time was
continuously determined to null the signal from normal
myocardium. Multiple 8 mm slices in the short-axis image
plane were acquired to cover the entire LV without gaps.
Myocardial fibrosis of the left ventricle was defined as
hyper-enhanced myocardium with a signal intensity (SI)
above 5 standard deviations from the SI in the normal
myocardium. The extent of hyper-enhancement in each
slice is determined and added up for total extent in grams
by the software cvi42 (Circle Cardiovascular Imaging
Inc., Calgary, Canada). All analyses were performed by
an experienced CMR physician (KA). Furthermore, all
LGE images were concomitantly analyzed and results
agreed upon by two experienced CMR physicians (KA
and NV); both blinded for other findings. The inter-
observer variation of LGE measurements has previously
been described [13].Electrocardiography
A 12-lead ECG was performed using a Burdick Atria 6100
ECG, Richmond, Australia. An abnormal ECG was defined
as the presence of; atrial flutter/fibrillation (AFL/AF),
atrioventricular block (AVB) grade I–III (AVB grade I:
PR-interval >220 ms), right and left bundle branch block
(RBBB/LBBB), QRS-interval >120 ms, incomplete right
bundle branch block (IRBBB) and prolonged QTc >450 ms
in males and >470 ms in females using Bazett’s formula
(QTc = QT/√RR).Holter-monitoring
A 48-hour Holter-monitoring was performed using a 3-
electrode Lifecard CF (Spacelabs Healthcare, Washington,
United States). Holter-monitoring was considered ab-
normal in the presence of; AVB grade I–III, AF/AFL,
other supraventricular tachyarrhythmia (SVT) (>30 sup-
raventricular premature contractions (SVPC) pr. hour
or runs of ≥20 SVPC), frequent ventricular premature
contractions (VPCs) (≥30/h) and non-sustained VT
(NSVT) (minimum of 3 beats at ≥100 bpm).Transthoracic echocardiography and left ventricular
longitudinal strain analysis
Transthoracic echocardiography was performed using
a Vivid e9 (General Electric, Horten, Norway). LV cavity
dimensions, mass and wall thickness and diastolic dys-
function were assessed in accordance with the recommen-
dations of the European Association of Echocardiography
and the American Society of Echocardiography [14,15].
LV longitudinal function was assessed with global longi-
tudinal strain (GLS) using a semiautomatic algorithm
(Automated Function Imaging (AFI), GE), (normal refer-
ence GLS ≤ −15.9%) [16].
An abnormal echocardiography was defined as left ven-
tricular ejection fraction ≤50%, left ventricular end dia-
stolic diameter (LVEDD) >53 mm (women) and >59 mm
(men), interventricular septum (IVS) >11 mm, left atrial
volume indexed (LA vol.) >34 ml/m2 and GLS > −15.9%.
Additionally, echocardiography was used to assess valve
disease and to estimate LV mass [14].
Muscle strength analysis
Muscle strength was graded using the Medical Research
Council scale (MRC) 0–5 (0 = no ability to contract
muscle, 5 = normal strength). Early affection occurs pri-
marily in the distal muscles in patients with DM1. There-
fore, we investigated the association between handgrip
(dominant hand) and ankle dorsal flexion and the pres-
ence of myocardial fibrosis on CMR.
Statistics
Data were analyzed with IBM SPSS Statistics version 19.
Two sided p-values were calculated for all analyses;
values ≤0.05 were considered statistically significant. Nor-
mally distributed values are expressed as means ± SD. Data
with skewed distribution is given as median (range).
Categorical variables were summarized by frequency
counts (percentage) and differences between groups were
evaluated using chi-square test. Comparisons between cat-
egories were made with Mann–Whitney U test. Correlation
analyses were performed using Spearman Correlation.
The patients included for CMR (n=30) were divided into
two groups: one with (n=18) and one without (n=12) ab-
normal findings on ECG and Holter-monitoring to evalu-
ate whether abnormal findings on conventional cardiac
assessment were associated with fibrosis. Sample size cal-
culation was based on the hypothesis that a minority of
patients without abnormal findings on ECG and Holter-
monitoring would have myocardial fibrosis (maximum
prevalence 5%). In contrast, we would expect myocardial
fibrosis to be present in the majority of patients (app.
prevalence 60%) with abnormal findings on ECG and
Holter-monitoring, corresponding to a total sample size of
28 patients with a power of 90%, and a two-sided alpha-
level of 5%.
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Study population
A total of 30 patients (17 men with a mean (SD) age
of 47 (14) years) were included for CMR: 18 patients
with, and 12 patients without abnormal findings on ECG
and Holter-monitoring (Table 1). Patients with abnormal
findings on ECG and/or Holter had higher NT-proBNP
(Table 1). None complained of cardiac symptoms includ-
ing palpitations, dizziness, chest pain, dyspnoea, periph-
eral oedema or syncope.
Cardiovascular magnetic resonance
Myocardial fibrosis of the left ventricle was found in 12/
30 patients (40%, 9 men) with a median LGE quantity of
4 g (range 1–17 g) (Figures 2 and 3). All patients were in
sinus rhythm at time of the CMR. Gender specific CMR
results are presented in Table 2.
The presence of myocardial fibrosis, independently of
quantity, was associated with the following CMR param-
eters: increased left ventricular mass, increased left atrial
volume and a trend toward lower LVEF (Table 3). Two
patients had reduced LVEF of 38% and 50% and con-
comitant myocardial fibrosis. Myocardial fibrosis did not
correlate with age (Spearman correlation r = 0.20, p =
0.28).
Myocardial fibrosis was heterogeneously located in the
left ventricle: anterior (n = 2), posterior (n = 1), anterior-
septal (n = 3), posterior-basal (n = 1) and lateral segments
(n = 2). Of these nine patients, six had concomitant fi-
brosis of the anterior (n = 1), posterior (n = 4) and both
hinge points (n = 1) between the right and left ventricle.
Three patients had isolated prominent hinge point fibro-
sis, related to the anterior, posterior, and both hinge
points, respectively. No fibrotic lesions were observed in
the right ventricle.
ECG
With regard to the pre-selected DM1 subgroups, myo-
cardial fibrosis was found in 8/18 (44%) of the patients
with abnormal findings on ECG and Holter-monitoring
and interestingly in 4/12 (33%) of the patients with nor-
mal findings on ECG and Holter (p = 0.71).
Selected ECG, echocardiographic and Holter-monitoring
results in patients with and without myocardial fibrosis are
summarized in Table 3. Myocardial fibrosis was associated
with IRBBB. There was no association between the pres-
ence of myocardial fibrosis and the following ECG parame-
ters: AVB grade I, LBBB and prolonged QTc (Table 3).
Overall, 7/30 patients (23%) had myocardial fibrosis and
one or several abnormal findings on the ECG vs. 5/30
(17%) patients with myocardial fibrosis and normal
ECG (p = 0.71).
The quantity of LGE did not correlate with the follow-
ing parameters: PR interval (Spearman correlation r =0.01, p = 0.97), QRS interval (r = 0.23, p = 0.22) or QTc-
interval (r = 0.10, p = 0.59).
Holter-monitoring
The prevalence of abnormal findings on Holter-
monitoring in patients with (n = 12) and without fibrosis
(n = 18) was: AF/AFL (3/12 vs. 1/18, p = 0.27), SVT (2/
12 vs. 0/18, p = 0.15), AVB grade II (0/12 vs. 3/18, p =
0.25), frequent VPC (2/12 vs. 2/18, p = 1.00), NSVT
(1/12 vs. 0/18, p = 0.40). As reported, three patients
(men, aged 46, 53 and 68 years) had paroxysmal atrial
fibrillation and concomitant myocardial fibrosis, and one
patient (a 46-year-old man) had permanent atrial fibrilla-
tion and flutter, which was terminated with radiofre-
quency ablation prior to CMR. Overall, no association
was observed between myocardial fibrosis and abnormal
findings on Holter-monitoring, i.e. 6/30 (20%) had myo-
cardial fibrosis and abnormal Holter-monitoring vs. 6/30
(20%) with myocardial fibrosis and normal Holter-
findings (p = 0.27).
The quantity of LGE did not correlate with the num-
ber of VPC/h (Spearman correlation r = 0.24, p = 0.20).
Echocardiography
When we added echocardiographic findings to the pre-
selected DM1-subgroups, a total of 21/30 patients had
abnormal findings on ECG, Holter-monitoring and/or
echocardiography, and of these 21 patients, myocardial
fibrosis was present in 9 (43%). Of the remaining 9 pa-
tients with normal routine cardiac screening 3 (33%) had
myocardial fibrosis. Taken together, no statistically sig-
nificant association was observed between the presence
of myocardial fibrosis and cardiac involvement on rou-
tine cardiac screening (p = 0.70).
There was no overall association between abnormal
findings on echocardiography and myocardial fibrosis
on CMR, i.e. 4/30 (13%) had myocardial fibrosis and
abnormal echocardiography vs. 8/30 (27%) with myocardial
fibrosis and normal echocardiography (p = 0.18). Further-
more, there was no association between myocardial fibrosis
and the following specific echocardiographic parameters:
LVEF ≤50% (2/12 vs. 1/18, p = 0.55), IVSD >11 mm (1/12
vs. 1/18, p = 1.00), abnormal LVEDD (3/12 vs. 2/18,
p = 0.36), LA vol. >34 ml/m2 (2/10 vs. 0/18, p = 0.12)
and abnormal GLS (3/10 vs. 2/16, p = 0.34).
The quantity of myocardial fibrosis correlated signifi-
cantly with LA volume (Spearman correlation r = 0.40,
p = 0.03), but there was no correlation with the remaining
echocardiographic parameters: IVSD (r = −0.10, p = 0.59),
LVIDD (r = 0.25, p = 0.18), LVEF (r = −0.19, p = 0.31), E/E’
(r = 0.14, p = 0.50), E/A (r = −0.05, p = 0.79), GLS (r = 0.13,
p = 0.54) and LV mass (r = 0.05, p = 0.81). One patient (a
57-year-old man) had increased LV mass of 141 g/m2 and
concomitant myocardial fibrosis.









N 12 18 -
Gender 7 men, 5 women 10 men, 8 women 1.00
Age (years),
mean (SD)




115 (11) 126 (19) 0.09
DBP (mmHg),
mean (SD)
74 (10) 76 (11) 0.64
Cardiac
medications
B-blocker (n) 1 1 1.00







8 (1–29) 13 (1–41) 0.02
Myoblobin (ug/l),
median (range)
68 (27–255) 103 (44–258) 0.22
CK (U/l),
median (range)













179 (130–200) 240 (160–260) 0.006
QRS interval (ms),
median (range)
88 (70–110) 96 (78–160) 0.24
QTc interval (ms),
median (range)
394 (346–451) 417 (360–516) 0.06
AVB grade I (n) 0 10 0.002
LBBB (n) 0 1 1.00
IRBBB (n) 0 4 0.13
Holter-monitoring
AVB grade II (n) 0 3 0.25
AF/AFL (n) 0 4 0.13
SVT (n) 0 2 0.50
NSVT (n) 0 1 1.00
VPC/h,
median (range)
0 (0–15) 4 (0–421) 0.004
Table 1 Clinical and cardiac findings in patients with DM1




57 (48–67) 58 (45–67) 0.72
IVS (mm),
median (range)
8 (6–13) 8 (5–11) 0.87
LVEDD (mm),
median (range)
46 (40–60) 47 (41–56) 0.97
LVPW (mm),
median (range)
7 (6–12) 8 (5–11) 0.70
LV mass (g/m2),
median (range)
70 (49–90) 70 (46–141) 0.90
LA vol. (ml/m2),
median (range)
22 (14–36) 25 (17–38) 0.50
GLS avg. (%),
median (range)
−19 (−14 to −23) −18 (−14 to −25) 0.66





DBP: diastolic blood pressure.
GLS: global longitudinal strain.
IRBBB: incomplete right bundle branch block.
IVS: interventricular septum.
LA vol.: left atrial volume.
LBBB: left bundle branch block.
LVEDD: left ventricular end diastolic diameter in diastole.
LVEF: left ventricular ejection fraction.
LV mass: left ventricular mass.
LVPW: left ventricular posterior wall.
MRC: medical research council scale.
NSVT: non-sustained ventricular tachycardia.
SVT: supraventricular tachycardia.
SBP: systolic blood pressure
VPC/h: ventricular premature contractions/hour.
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(36 and 38 ml/m2, respectively) but no other signs of
diastolic dysfunction. Echocardiography excluded signifi-
cant valve disease.
Discussion
This study demonstrates that adult patients with DM1
have a high prevalence of myocardial fibrosis (40%).
Myocardial fibrosis was associated with increased left
ventricular mass, increased LA volume and a trend to-
ward lower LVEF assessed by CMR. On standard cardiac
screening, myocardial fibrosis was associated with IRBBB
and correlated with LA volume assessed by echocardio-
graphy. Nevertheless, a normal ECG, echocardio-graphy
and/or Holter-monitoring could not rule out the pres-
ence of myocardial fibrosis on CMR.
Physicians treating and referring patients with DM1 face
a major challenge in handling the risk of SCD in these
patients. Risk predictors for SCD in patients with DM1
are needed and specific ECG abnormalities, such as atrial
tachyarrhythmia and AVB, are already known predictors
of SCD [2]. Studies have reported a correlation between
Figure 2 Late gadolinium enhancement. Representative images (long-axis on the left and short-axis on the right) of late gadolinium enhancement
(marked with red arrows) in a 63-year-old woman with concomitant atrioventricular block grade I and frequent ventricular premature contractions
on Holter-monitoring.
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ciation between ECG abnormalities and abnormal CMR
findings in DM1 patients [17-19]. Nevertheless, myocar-
dial fibrosis in DM1 patients has only been investigated
in few studies [17-21]. Although these studies are not
directly comparable due to different CMR-techniques,
myocardial fibrosis has been reported with prevalence
ranging from 10 to 40%, i.e. in the order of magnitude
as presently found. Our study is the first to evaluate the
association between myocardial fibrosis on CMR and a
systematic standard cardiac screening including ECG,
Holter-monitoring and echocardiography. A recent CMR-
study including 80 patients with DM1 reported myocardial
fibrosis in 10 patients (13%) and 9/10 had concomitant
abnormal ECG [18]. In comparison, we found a higher
prevalence of patients with myocardial fibrosis (40%) and
no association between myocardial fibrosis and abnormal
ECG findings. The above findings substantiate that myo-
cardial fibrosis has an impact on the pathogenic process of
DM1, although not necessarily related to the findings
based on routine cardiac evaluation [17-21].Figure 3 Late gadolinium enhancement. Representative short-axis imag
posterior left ventricular wall, and of the midwall and posterior hinge point
comparison, normal findings are illustrated on the right.In several cardiomyopathies, myocardial fibrosis seems
to act as a substrate for ventricular arrhythmias. Fur-
thermore, myocardial fibrosis is a dominant finding in
endomyocardial biopsies from patients with spontaneous
ventricular fibrillation and no other macroscopic cardiac
disease [22-26]. Additionally, studies have demonstrated
an association between the quantity of myocardial fibrosis
and the risk of ventricular arrhythmias [27-30]. In patients
with DM1, myocardial fibrosis has been observed in
autopsy findings and in pathology studies with animal-
models of DM1 [6-8,31-35], giving evidence of a pos-
sible link between myocardial fibrosis and ventricular
arrhythmias, which may lead to SCD. Skeletal muscle
biopsies have also revealed fibrotic changes together
with muscle fiber diameter variation, adipose deposition
and a high number of central nuclei [36]. So far, there is
no definitive pathogenic explanation for these histo-
pathological alterations, although combined effects of mis-
regulated splicing of several genes involved in calcium
regulation and extracellular coupling may contribute to
the muscle degeneration [37,38]. Nonetheless, myocardiale (left) showing late gadolinium enhancement of the lateral and
(red arrows) in a 58-year-old man with concomitant AVB grade I. In
Table 2 Gender-specific CMR results in patients with DM1
All Men Women
Myocardial fibrosis, n (%) 12 (40) 9 (75) 3 (25)
LGE (g), median (range) 4 (1–17) 4 (3–17) 3 (1–10)
LVEF (%), median (range) 63 (38–71) 60 (38–65) 66 (63–71)
LVEF ≤ 50%, n (%) 2 (17) 2 (22) 0
LVEDV (ml/m2), median (range) 83 (53–130) 89 (61–130) 75 (53–75)
LVESV (ml/m2), median (range) 31 (15–73) 33 (22–73) 26 (15–28)
LV mass (g/m2), median (range) 55 (43–83) 58 (47–83) 44 (43–4550)
LA vol. (ml/m2), median (range) 52 (36–87) 56 (46–87) 45 (36–49)
LGE: late gadolinium enhancement.
LV mass: left ventricular mass.
LVEDD: left ventricular end diastolic diameter in diastole.
LVEDV: left ventricular end diastolic volume.
LVEF: left ventricular ejection fraction.
LVESV: left ventricular end systolic volume.
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mechanism in both skeletal and cardiac muscle. In pa-
tients with hypertrophic cardiomyopathy, hypertrophy and
interstitial fibrosis are important determinants of morbid-
ity and mortality [39,40] and the changes are suggested to
occur as a response to trophic and fibrotic factors such as
levels of angiotensin II [41]. Transforming growth factor
(TGF)-β is an important mediator of pro-fibrotic signals,
and early inhibition of TGF-β e.g. with ACE-inhibitors has
shown to diminish the development of fibrosis and hyper-
trophy independent of blood pressure [42]. A recent case-
report presented a 50-year-old DM1 patient who suddenly
died due to malignant arrhythmia [35]. Autopsy revealed a
normal sized heart with no atherosclerotic lesions, but
patchy fibrosis involving 20% of the left and right ventricu-
lar myocardium and a strong immune-positive result of
TGF-β expression. This case was considered by the au-
thors to indicate an association between TGF-β and the fi-
brotic lesions in DM1. In addition, studies have shown
that ACE-inhibitors, or ACE-inhibitors in combination
with beta-blockers, delay the progression of cardiomyop-
athy in patients with Duchenne muscular dystrophy
(DMD), and has a beneficial effect on long-term survival
of DMD patients with heart failure [40,43]. As there are
some phenotypic similarities between patients with DM1
and DMD, a similar beneficial pharmacological effect may
exist in patients with DM1. Early treatment with ACE-
inhibitors should therefore be considered and need further
investigation in relation to SCD in DM1.
So far, no homogeneous LGE pattern has been described
in DM1, which is in accordance with our findings [18,20].
However, it seems that mid-myocardial enhancement is
most often observed in the septal and basal lateral seg-
ments [18,20]. Mid-wall fibrosis in patients with non-
ischaemic dilated cardiomyopathy provides independent
prognostic information and improves risk stratification
beyond LVEF for all-cause mortality and SCD [44].Isolated RV-insertion point enhancement was observed
in three patients, which can also be observed in healthy
individuals, usually as tiny faint enhancement. However,
the insertion point fibrosis observed in these patients
was prominent and more pronounced than what is seen
in healthy individuals. We need to reassess our DM1
patients with CMR, before we can document the prog-
nostic information related not only to the localization
but also to the progression of myocardial fibrosis in
DM1.
Taken together, myocardial fibrosis may play a central
role in the pathogenic process in DM1. Our findings
emphasize that CMR add additional information to
current screening procedures with a potential major im-
pact on future risk stratification for SCD. Assuming that
myocardial fibrosis is a predictor of cardiac outcome,
CMR may be a unique tool for identifying high-risk
DM1 patients in order to optimize early treatment and
prevent SCD.
Longitudinal studies are needed to investigate the prog-
nostic value of myocardial fibrosis and to assess whether
improved periodic cardiac assessment, based on the pres-
ence, progression and degree of myocardial fibrosis, can
prevent life-threatening brady- and tachyarrhythmias
through optimized medical treatment and implantation
of PMs and ICDs.
Study limitations
Contrast enhanced CMR is a well-established technique
to assess focal myocardial fibrosis. We did not assess the
degree of diffuse myocardial fibrosis, hence, we may
underestimate and even oversee the fibrotic burden in
some patients.
Some patients were not eligible for CMR due to ventila-
tory assist devices or claustrophobia and few patients re-
fused to participate due to severe muscular impairment.
The exclusion of patients with the most severe muscular
Table 3 Clinical characteristics and CMR-results in








51 (18) 44 (10) 0.28
SBP (mmHg),
mean (SD)
128 (104–168) 117 (97–135) 0.17
DBP (mmHg),
mean (SD)
78 (65–95) 73 (56–101) 0.14
NT-ProBNP (pmol/l),
median (range)
9 (1–18) 11 (1–41) 0.38
Myoblobin (ug/l),
median (range)
103 (34–162) 69 (27–258) 0.56
CK (U/l),
median (range)
199 (56–498) 162 (42–780) 0.61
Handgrip (MRC),
median (range)








63 (38–71) 66 (60–80) 0.06
LGE (g),
median (range)
4 (1–17) 0 <0.001
LVEF ≤ 50%,
n (%)
2 (17) 0 0.15
LVEDV (ml/m2),
median (range)
83 (53–130) 71 (57–108) 0.16
LVESV (ml/m2),
median (range)
31 (15–73) 25 (13–43) 0.03
LV mass (g/m2),
median (range)
55 (43–83) 46 (36–64) 0.02
LA vol. (ml/m2),
median (range)




191 (160–220) 190 (130–260) 0.85
QRS interval (ms),
median (range)
96 (70–160) 86 (78–120) 0.43
QTc interval (ms),
median (range)
411 (360–516) 407 (346–478) 0.66
AVB grade I 3 7 0.69
LBBB 1 0 0.40
IRBBB 4 0 0.02
Holter-monitoring
AVB grade II 0 3 0.25
AF/AFL 3 1 0.27
SVT 2 0 0.15
NSVT 1 0 0.40
VPC/h,
median (range)
3 (0–421) 0 (0–69) 0.30
Table 3 Clinical characteristics and CMR-results in




57 (45–53) 58 (48–67) 0.34
IVS (mm),
median (range)
8 (5–11) 8 (6–13) 0.83
LVEDD (mm),
median (range)
50 (40–60) 46 (40–60) 0.24
LVPW (mm),
median (range)
8 (5–11) 7 (6–12) 0.77
LV mass (g/m2),
median (range)
74 (47–141) 68 (46–87) 0.74
LA vol. (ml/m2),
median (range)
26 (17–38) 24 (14–29) 0.08
GLS avg. (%),
median (range)
−19 (−14 to −23) −18 (−14 to −25) 0.75
E/A 1.2 (0.6-2.6) 1.4 (0.8-2.4) 0.69
E/E’ (lateral) 5.4 (3.5-7.4) 4.9 (3.6-8.2) 0.39
MV dec. time (ms) 150 (91–214) 157 (107–239) 0.81





DBP: diastolic blood pressure.
GLS: global longitudinal strain.
IRBBB: incomplete right bundle branch block.
IVS: interventricular septum.
LA vol: left atrial volume.
LBBB: left bundle branch block.
LGE: late gadolinium enhancement.
LV mass: left ventricular mass.
LVEDD: left ventricular end diastolic diameter in diastole.
LVEDV: left ventricular end diastolic volume.
LVEF: left ventricular ejection fraction.
LVESV: left ventricular end systolic volume.
LVPW: left ventricular posterior wall.
MRC: medical research council scale.
MV dec. time: mitral valve deceleration time.
NSVT: non-sustained ventricular tachycardia.
SBP: systolic blood pressure.
SVT: supraventricular tachycardia.
VPC/h: ventricular premature contractions/hour.
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http://jcmr-online.com/content/16/1/59and respiratory impairment represents selection bias. How-
ever, we believe this would be a common bias for all CMR
studies in this field. Furthermore, if these patients would
have more cardiac involvement than the remaining pa-
tients, it would probably skew our results towards substan-
tiating our conclusion that myocardial fibrosis is a frequent
finding in patients with DM1.
Several studies have assessed the correlation between
CTG repeat length and cardiac involvement with am-
biguous results [3,45]. A recent study reported a large
inter- and intra-tissue CTG length variation in DM1 tis-
sue with the largest expansion in the heart and cerebral
cortex [46]. These observations strongly indicate that
factors other than genetic are responsible for the ob-
served cardiac involvement in DM1 and explain why
Petri et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:59 Page 9 of 10
http://jcmr-online.com/content/16/1/59CTG-repeat length is only estimated for diagnostic
purposes.
Due to the relatively small number of patients in our
study, the impact of our findings on the clinical manage-
ment of patients with DM1 is limited and needs to be
assessed in larger studies.
Conclusion
CMR documented a high prevalence of myocardial fibrosis
in patients with DM1. Overall, myocardial fibrosis was
mainly observed in patients with concomitant abnormal
findings on ECG, Holter-monitoring and/or echocardio-
graphy. Nevertheless, myocardial fibrosis was also present
in 33% of the patients with normal findings on routine
cardiac screening. These findings emphasize that a normal
ECG, Holter-monitoring and echocardiography cannot
exclude myocardial fibrosis.
CMR adds additional information to the current stand-
ard cardiac assessment and might be a valuable tool for
risk stratification in DM1. The progression and the prog-
nostic value of myocardial fibrosis needs to be further
investigated in longitudinal studies.
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